MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Pfizer DPO Ratio 2011-2025 | PFE
Annual DPO Ratio Pfizer
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126 | 98.9 | 65.8 | 58.5 | 183 | 151 | 152 | 151 | 134 | 137 | 131 | 123 | 137 | 92.8 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 183 | 58.5 | 124 |
Quarterly DPO Ratio Pfizer
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 111 | 126 | 169 | 90.3 | 148 | 148 | 56.2 | 172 | 121 | - | 93.9 | 61.8 | 50.6 | - | 41.5 | 54.7 | 91.6 | - | 196 | 215 | 193 | - | 148 | 149 | 167 | - | 158 | 146 | 166 | - | 149 | 160 | - | - | - | - | - | - | - | - | - | - | - | - | 144 | - | 129 | 132 | 124 | - | 115 | 138 | 132 | - | 98.5 | 90.1 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 215 | 41.5 | 128 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
23 | $ 4.78 | -0.31 % | $ 793 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
887 | $ 3.03 | -0.49 % | $ 234 M |  USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
405 | $ 1.15 | -1.71 % | $ 6.27 M |  China |
 |
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Aptevo Therapeutics
APVO
|
239 | $ 0.6 | -35.8 % | $ 166 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M | Canada |
 |
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
28.5 | $ 27.09 | 1.04 % | $ 1.31 B | USA |
 |
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
54.4 | $ 9.6 | 1.27 % | $ 141 M | USA |
 |
Berkeley Lights
BLI
|
135 | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
182 | - | - | $ 546 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
142 | - | -6.81 % | $ 3.04 B | USA |
 |
Axon Enterprise
AXON
|
29.9 | $ 584.81 | -1.07 % | $ 44.3 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
186 | $ 2.44 | -3.56 % | $ 15.3 M | USA |
 |
AstraZeneca PLC
AZN
|
265 | $ 92.79 | 0.37 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
Catalyst Biosciences
CBIO
|
18.8 | $ 12.33 | -0.29 % | $ 812 M | USA |
 |
Brickell Biotech
BBI
|
105 | - | -5.38 % | $ 6.06 M | USA |
 |
Celldex Therapeutics
CLDX
|
6.17 K | $ 26.29 | -2.01 % | $ 1.69 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
199 | $ 11.07 | 2.45 % | $ 716 M | USA |